Alliances
Biohaven and Pfizer have partnered to market the Nurtec migraine medicine outside the U. S. once approved by global regulatory organizations. Here’s more about it.
Autolus is currently working on advancing obecabtagene autoleucel, its CD19 CAR T cell investigational therapy product candidate, in addition to other applications of obe-cel in B-cell malignancies.
For the past 20 years, Novartis has held a 33% stake in Roche, its Basel, Switzerland neighbor. Now, Novartis has divested its one-third stake to Roche for a whopping $20.7 billion.
This first-of-its-kind collaboration will leverage the talent and innovation at companies such as Tessera Therapeutics to advance multiple candidates to human proof of concept.
In November 2019, Emory realized this experimental drug could have significant potential in respiratory viruses such as COVID-19.
Shoreline Biosciences secured $140 million in financing to accelerate the growth of its induced pluripotent stem cells (iPSC)-based immunotherapies and support the expansion of its manufacturing capabilities.
The partnership will leverage Metagenomi’s novel gene editing technology and Moderna’s mRNA platform, in addition to its lipid nanoparticle delivery technologies.
Novartis has forged a collaboration with U.K.-startup Dunad Therapeutics to develop next-generation targeted protein-degradation therapies in a deal valued at up to $1.3 billion.
This novel diagnostic technology uses augmented reality and a smartphone or tablet to administer cognitive and functional tests.
Inovio shares are down about 2% in premarket trading after cancellation reports of a DNA cancer vaccine collab with AstraZeneca.
PRESS RELEASES